Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 7;16(1):e0245035. doi: 10.1371/journal.pone.0245035

The value of TI-RADS combined with superb microvascular imaging in distinguishing thyroid nodules: A protocol for systematic review and meta-analysis

Cong Wang 1,#, Mingxin Lin 1,#, Lin Zhong 2,*, Congliang Tian 3,*
Editor: Oded Cohen4
PMCID: PMC7790367  PMID: 33411820

Abstract

Background

As a novel ultrasonic technique, superb microvascular imaging (SMI) can quickly, simply and noninvasively observe the microvascular distribution in a tumor and evaluate the microvascular perfusion. Previous studies have shown that SMI can detect the blood flow signals of neovascularization in tumors and increase the sensitivity for detecting thyroid cancer. However, the results of these studies have been contradictory, and the sample sizes were too small. Therefore, the present meta-analysis will aim at evaluating the value of a thyroid imaging report and data system (TI-RADS) combined with SMI in distinguishing between benign and malignant thyroid nodules.

Methods

We will search PubMed, Web of Science, Cochrane Library, Google Scholar, and Chinese biomedical databases from their inceptions to the June 31, 2020. Two authors will independently carry out searching literature records; scanning titles, abstracts, and full texts; collecting data; and assessing risk of bias. Review Manager 5.2 and Stata14.0 software will be used for data analysis.

Results

This systematic review will evaluate the value of TI-RADS combined with SMI in distinguishing between benign and malignant thyroid nodules.

Systematic review registration

INPLASY202070113.

Introduction

Thyroid cancer is a very common malignant disease that accounts for approximately 1% of all cancer patients [1]. A solid thyroid nodule is a risk factor for thyroid cancer, so it is very important to differentiate thyroid nodules effectively and in a timely manner [2]. Ultrasonography has the advantage of high sensitivity in the diagnosis of a thyroid nodule, and it is the first choice for the clinical diagnosis and differentiation of thyroid cancer [3]. In 2017, the American College of Radiology (ACR) proposed the latest version of thyroid imaging report and data system (TI-RADS) classification, ACR TI-RADS, based on large-scale, evidence-based clinical validation, which greatly promotes the differentiation of benign and malignant thyroid nodules [4]. However, due to the complexity and overlapping of the sonograms of thyroid nodules, it is still difficult to accurately identify some nodules with atypical ultrasound characteristics [5]. There are some differences in blood flow pattern and vascular morphology between benign and malignant thyroid nodules, which is helpful in distinguishing between benign and malignant thyroid nodules [6]. Color Doppler flow imaging (CDFI) is often used to show the blood flow inside the tumor, but CDFI is not good for some low-velocity microvessels and is not useful in distinguishing thyroid nodules [7,8]. As a novel ultrasonic technique, SMI can quickly, simply and noninvasively observe the microvascular distribution in the tumor and evaluate the microvascular perfusion [9]. Previous studies have shown that SMI can detect the blood flow signals of neovascularization in tumors and increase the sensitivity for detecting thyroid cancer [1013]. However, the results of these studies have been contradictory, and the sample sizes were too small. Therefore, the present meta-analysis aimed at evaluating the value of TI-RADS combined with SMI in distinguishing between benign and malignant thyroid nodules.

Materials and methods

This study will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the protocol was registered in the INPLASY (INPLASY202070113).

Eligibility criteria

Type of study

This study will only include high-quality clinical cohorts or case control studies.

Type of patients

The patients had all been diagnosed with a thyroid nodule.

Intervention and comparison

Thyroid nodules of all patients were assessed with TI-RADS alone and with TI-RADS combined with SMI.

Type of outcomes

The primary outcomes include the area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve, as thyroid nodules were assessed by means of TI-RADS alone and TI-RADS combined with SMI.

Search methods

PubMed, Web of Science, Cochrane Library, Google Scholar and Chinese biomedical databases will be searched from their inceptions to the June 31, 2020. The search strategy for PubMed is shown in Table 1. Other online databases will be used with the same strategy.

Table 1. Search strategy sample of PubMed.

Number Search terms
1 thyroid cancer or thyroid neoplasm or thyroid tumor or thyroid nodule
2 thyroid imaging report and data system or TI-RADS
3 superb microvascular imaging or superb micro-vascular imaging
4 and 1–3

Data extraction and quality assessment

Two authors will independently selecte the trials according to the inclusion criteria and imported them into Endnote X9. Then, the duplicated or ineligible studies will be removed. Afterwards, the titles, abstracts, and full texts of all the literature will be screened to identify eligible studies. All essential data will be extracted using the data collection sheet previously created by 2 independent authors. Discrepancies in data collection between the 2 authors will be settled through discussion with the help of another author. The following data will be extracted from each included study: the first author's surname, publication year, language of publication, study design, sample size, number of lesions, source of the subjects, "gold standard," and diagnostic accuracy. The true positives (TPs), true negatives (TNs), false positives (FPs), and false negatives (FNs) in the fourfold (2 x 2) tables will also be collected. Methodological quality will be assessed by two researchers independently based on the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool [14]. The QUADAS criteria includes 14 assessment items. Each of these items was scored as "yes" (2), "no" (0), or "unclear" (1). The QUADAS score ranged from 0 to 28, and a score ≥ 22 indicated good quality.

Statistical analysis

STATA version 14.0 (Stata Corp, College Station, TX, USA), Meta-Disc version 1.4 (Universidad Complutense, Madrid, Spain), and MedCalc version 15.2.2 (MedCalc Software, Ostend, Belgium) software will be used for meta-analysis. We will calculate the pooled summary statistics for sensitivity (Sen) and specificity (Spe) with their 95% confidence intervals (CIs). The summary receiver operating characteristic (SROC) curve and corresponding area under the curve (AUC) were obtained. We will compare the two AUCs of TI-RADS alone and TI-RADS combined with SMI. Cochran’s Q-statistic and I2 test will be used to evaluate potential heterogeneity between studies. If the Q-test showes a P < 0.05 or I2 test exhibited > 50%, indicating significant heterogeneity, the random-effects model will be employed, or if heterogeneity is not significant, the fixed-effects model will be used. We will conduct Begg's funnel plots and Egger's linear regression tests to investigate publication bias. Sensitivity analysis will be performed to evaluate the influence of a single study on the overall estimate.

Ethics and dissemination

We will not obtain ethics documents because this study will be conducted based on the data of published literature. We expect to publish this study in a peer-reviewed journal.

Discussion

Thyroid nodules are a common clinical disease, and their accurate differentiation has important guiding significance for clinical decision-making. High resolution ultrasound plays an important role in the differential diagnosis of thyroid nodules [13]. Although ultrasound features of malignant thyroid nodules, such as low echo, unclear margin, microcalcifications and aspect ratio > 1, increase the risk of evaluation of malignant nodules, no single ultrasound feature can independently diagnose malignant thyroid nodules [15]. Present studies have revealed that SMI was able to identify low-velocity blood flow without being affected by motion artifacts, and as an adjunct to grayscale ultrasound, SMI showed a significantly improved diagnostic performance in differentiating between benign and malignant thyroid nodules [16]. The present meta-analysis aims at evaluating the value of thyroid imaging report and data system (TI-RADS) combined with SMI in distinguishing between benign and malignant thyroid nodules and to provide evidence on the evidence-based medical support for clinical practice.

Supporting information

S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: Recommended items to address in a systematic review protocol*.

(DOC)

S1 File

(PDF)

Data Availability

All relevant data from this study will be made available upon study completion.

Funding Statement

This study is supported by Liaoning Natural Science Foundation Project (20170540256). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26: 1–133. 10.1089/thy.2015.0020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13: 184–199. 10.1038/nrc3431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Valderrabano P, McIver B. Evaluation and management of indeterminate thyroid nodules: the revolution of risk stratification beyond cytological diagnosis. Cancer Control. 2017;24: 1073274817729231 10.1177/1073274817729231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lauria Pantano A, Maddaloni E, Briganti SI, Beretta Anguissola G, Perrella E, Taffon C, et al. Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound classifications performance in identifying cytological high-risk thyroid nodules. Eur J Endocrinol. 2018;178: 595–603. 10.1530/EJE-18-0083 [DOI] [PubMed] [Google Scholar]
  • 5.Woliński K, Szkudlarek M, Szczepanek-Parulska E, Ruchała M. Usefulness of different ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of prospective studies. Pol Arch Med Wewn. 2014;124: 97–104. 10.20452/pamw.2132 [DOI] [PubMed] [Google Scholar]
  • 6.De Nicola H, Szejnfeld J, Logullo AF, Wolosker AM, Souza LR, Chiferi V Jr., Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms. J Ultrasound Med. 2005;24: 897–904. 10.7863/jum.2005.24.7.897 [DOI] [PubMed] [Google Scholar]
  • 7.Wang XN, Zhao Q, Li DJ, Wang ZY, Chen W, Li YF, et al. Quantitative evaluation of primary retinitis pigmentosa patients using colour Doppler flow imaging and optical coherence tomography angiography. Acta Ophthalmol. 2019;97: e993–e997. 10.1111/aos.14047 [DOI] [PubMed] [Google Scholar]
  • 8.J Matthew Debnam Thinh Vu, Sun Jia, et al. Vascular flow on doppler sonography may not be a valid characteristic to distinguish colloid nodules from papillary thyroid carcinoma even when accounting for nodular size. Gland Surg. 2019;8:461–468. 10.21037/gs.2019.08.06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hata T, Koyanagi A, Yamanishi T, Bouno S, Takayoshi R, Miyake T. Superb microvascular imaging with Doppler luminance using an 18-MHz probe to visualize fetal intra-abdominal blood vessels and organ microvasculature. J Perinat Med. 2020;48: 184–188. 10.1515/jpm-2019-0411 [DOI] [PubMed] [Google Scholar]
  • 10.Cappelli C, Pirola I, Gandossi E, Marini F, Cristiano A, Casella C, et al. Ultrasound microvascular blood flow evaluation: a new tool for the management of thyroid nodule? Int J Endocrinol. 2019;2019: 7874890 10.1155/2019/7874890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ahn HS, Lee JB, Seo M, Park SH, Choi BI. Distinguishing benign from malignant thyroid nodules using thyroid ultrasonography: utility of adding superb microvascular imaging and elastography. Radiol Med. 2018;123: 260–270. 10.1007/s11547-017-0839-2 [DOI] [PubMed] [Google Scholar]
  • 12.Kong J, Li JC, Wang HY, Wang YH, Zhao RN, Zhang Y, et al. Role of superb micro-vascular imaging in the preoperative evaluation of thyroid nodules: comparison with power doppler flow imaging. J Ultrasound Med. 2017;36: 1329–1337. 10.7863/ultra.16.07004 [DOI] [PubMed] [Google Scholar]
  • 13.Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract. 2010;16: 468–475. 10.4158/EP.16.3.468 [DOI] [PubMed] [Google Scholar]
  • 14.Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6: 9 10.1186/1471-2288-6-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Cohen O, Lahav G, Schindel D, Halperin D. Surgeon performed thyroid and neck ultrasound as a tool for better patient care. Harefuah. 2020;159: 128–131. [PubMed] [Google Scholar]
  • 16.Nguemgo Kouam P, Bühler H, Hero T, Adamietz IA. The increased adhesion of tumor cells to endothelial cells after irradiation can be reduced by FAK-inhibition. Radiat Oncol. 2019;14: 25 10.1186/s13014-019-1230-3 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Oded Cohen

14 Sep 2020

PONE-D-20-23187

The value of TI-RADS combined with superb microvascular imagine in distinguishing thyroid nodules: A protocol for systematic review and meta-analysis

PLOS ONE

Dear Dr. Tian,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 09/10/2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Oded Cohen

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following financial disclosure:

 [Initials of the authors who received each award. The funders  will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Additional Editor Comments (if provided):

The authors should use Google Scholar as a search engine or to explain why particular search engines were chosen

The headline refers to both systematic review and meta-analysis while the abstract refers to systematic review alone. As this are two distinct entities, the authors should clarify which type of work is about to be done

The authors must adhere to the PRISMA protocol for systematic review and meta-analysis. This should be stated and carries out throughout the manuscript.

The authors should explain better current knowledge on regular Doppler and why it was not adopted for ACR TIRADS, and then address differences of regular Doppler and SMI

The type of studies is not well defined. Please adhere to the PRISMA protocols

How can the authors define 'without language restriction'? How do the plan to overcome this barrier in order to fully understand the articles?

Why does criteria 1 in table 1 needed? Please explain

Discussion does contain a 'will be' which will address the study's result.  Is it just the opening statement?

Decision Letter 1

Oded Cohen

22 Dec 2020

The value of TI-RADS combined with superb microvascular imagine in distinguishing thyroid nodules: A protocol for systematic review and meta-analysis

PONE-D-20-23187R1

Dear Dr. Congliang Tian,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Oded Cohen

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: It sounds like an interesting issue, The pattern of the blood flow in a tumor might be a tool for more precise US diagnosis. good luck

Reviewer #2: The study aims to evaluate the value of a thyroid imaging report and data system (TI-RADS) combined with SMI in distinguishing between benign and malignant thyroid nodules.

The study protocol is well written.

There authors should relate to risk of bias and dealing with missing data in the data extraction and quality assessment section.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Galit Avior

Reviewer #2: Yes: Sharon Tzelnick

Acceptance letter

Oded Cohen

28 Dec 2020

PONE-D-20-23187R1

The value of TI-RADS combined with superb microvascular imaging in distinguishing thyroid nodules: a protocol for systematic review and meta-analysis

Dear Dr. Tian:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Oded Cohen

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: Recommended items to address in a systematic review protocol*.

    (DOC)

    S1 File

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data from this study will be made available upon study completion.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES